Guide · Sources checked October 26, 2026
Published · Updated
Alcohol and GLP-1 medicines: what the evidence shows
The semaglutide and tirzepatide labels do not include a specific alcohol interaction, but several of their warnings overlap with effects of drinking. Small randomized trials published in 2025 and 2026 suggest semaglutide can reduce some measures of drinking, but no GLP-1 medicine is approved to treat alcohol use disorder.[1][4][5][2][3]
The semaglutide trials
In a 9-week phase 2 trial, 48 non-treatment-seeking adults with alcohol use disorder received weekly semaglutide or placebo. Semaglutide reduced alcohol consumed in a laboratory drinking session, drinks per drinking day, and weekly craving. It did not change average drinks per day or the number of drinking days. The authors called this initial evidence that justifies larger trials.[1]
In a 26-week trial published in The Lancet in 2026, 108 adults with alcohol use disorder and obesity received therapy plus semaglutide or placebo; heavy drinking days fell 13.7 percentage points more on semaglutide.[4] A 2026 trial of oral semaglutide in 50 adults missed its main goal, lab-measured craving, but reduced heavy drinking days.[5] Our full review of the trials and health-record studies is in Do Ozempic, Wegovy and Zepbound make you drink less?
Label warnings that overlap with drinking
- Gastrointestinal effects: nausea was reported in 44% of Wegovy patients versus 16% on placebo, and vomiting in 24% versus 6%.[2]
- Kidney injury from dehydration: both labels warn about acute kidney injury, and Wegovy’s describes reports mostly in patients whose GI reactions led to dehydration.[2][3]
- Hypoglycemia: the Wegovy label says people with diabetes taking it with insulin or an insulin secretagogue such as a sulfonylurea may have a higher risk of low blood sugar, including severe episodes.[2]
What is not known
The trials were small and short (26 weeks at most) and did not test alcohol safety in people taking these drugs for weight loss.[1][4][5] Questions about drinking while on a specific medicine belong with the prescriber.
References
- Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-405. PMID 39937469. https://pubmed.ncbi.nlm.nih.gov/39937469/. Checked October 15, 2026.
- U.S. Food and Drug Administration. WEGOVY (semaglutide) injection prescribing information, revised 2025 (Table 2 and section 5.5). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf. Checked October 15, 2026.
- U.S. Food and Drug Administration. ZEPBOUND (tirzepatide) injection prescribing information, revised 2025 (Table 1 and section 5.3). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf. Checked October 15, 2026.
- Klausen MK, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026. PMID 42070571. https://pubmed.ncbi.nlm.nih.gov/42070571/. Checked October 26, 2026.
- Schacht JP, et al. Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial. Am J Psychiatry. 2026. PMID 42522065. https://pubmed.ncbi.nlm.nih.gov/42522065/. Checked October 26, 2026.
This page summarizes published research and regulatory documents. It is not medical advice and does not recommend starting, stopping, or changing any medication.